WallStSmart

Repro Med Systems Inc (KRMD)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 147479% more annual revenue ($66.57B vs $45.11M). MRK leads profitability with a 4.8% profit margin vs -4.0%. MRK earns a higher WallStSmart Score of 36/100 (F).

KRMD

Avoid

26

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 0.98

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KRMD.

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KRMD2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
18.2%8/10

18.2% revenue growth

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

KRMD4 concerns · Avg: 3.0/10
Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Market CapQuality
$147.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-13.5%2/10

ROE of -13.5% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : KRMD

The strongest argument for KRMD centers on Debt/Equity, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : KRMD

The primary concerns for KRMD are Price/Book, Market Cap, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

KRMD profiles as a growth stock while MRK is a value play — different risk/reward profiles.

KRMD carries more volatility with a beta of 0.45 — expect wider price swings.

KRMD is growing revenue faster at 18.2% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Repro Med Systems Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?